Leishmaniasis: Current Status and Future Perspectives
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Parasitic Pathogens".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 2341
Special Issue Editors
Interests: immunology; epidemiology; diagnosis and treatment of canine visceral leishmaniasis
Interests: leishmaniasis; Chagas disease; immunopathology; diagnosis; treatment; epidemiology; molecular biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Leishmaniasis stands as one of the most neglected diseases worldwide, presenting a significant challenge to control efforts. The escalating resistance to drugs employed in its treatment is an alarming trend. Despite attempts to mitigate the disease's vector, these efforts have largely proven ineffective, leading to its widespread prevalence across numerous countries. At present, there exists no anti-leishmaniasis vaccine for humans, and only one option available for preventing canine leishmaniasis (CanL) in Europe. However, even this option has restricted reach. In Brazil, a country bearing the brunt of visceral leishmaniasis cases in the Americas, all vaccines for CanL have been withdrawn from the market, leaving prevention strategies severely lacking. To combat the spread of the disease, Brazilian authorities have introduced novel measures such as the use of deltamethrin 4%-impregnated collars for dogs. Nonetheless, it is evident that further research is crucial to enhance vector control methods, develop new drugs or treatment regimens for both humans and animals, and advance the development of more effective vaccines.
Dr. Maria do Socorro Pires Cruz
Dr. Flávia de Oliveira Cardoso
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leishmaniasis
- control
- therapy
- epidemiology
- vector
- genetics
- immunotherapy
- prevention
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
